Trump Administration Halts Funding for Bird Flu Vaccine: Here's Why

The Trump administration has announced the cancellation of funding for the bird flu vaccine program in the United States. This controversial decision is reportedly based on budget priorities and concerns over vaccine efficacy. Critics argue it could leave the country vulnerable to future outbreaks, while proponents suggest reallocating funds for other pressing healthcare needs. Read on to understand the reasoning behind this move and its potential implications.
The Trump administration canceled the contract given to Moderna for the development of the final phase of the bird flu vaccine. Along with this, the right to buy shots has also been canceled.
In January, Moderna was given $590 million by the Biden administration to advance the development of its bird flu vaccine and pandemic influenza. This also includes supporting the expansion of five additional studies.
Earlier last year, additional funds of $176 million were given to complete the final phase development and testing of the mRNA-based vaccine. This was given by the US Department of Health and Human Services against H5N1 avian influenza.
What did the company say?
Moderna said it plans to explore options for the development and manufacture of the final phase of the vaccine.
The company also announced that it received positive interim data from tests to test the safety of its bird flu vaccine targeting the H5 avian influenza virus type.
When did the first case come?
The H5N1 bird flu outbreak was first reported in the US in April 2024, in which more than 70 people have been infected so far. Most of them are laborers. So far there has been no evidence of human-to-human transmission of this virus and hence the risk to the general public is low. But people who come in contact with birds, chickens or cattle are at higher risk of infection.
About the author
Related Posts
Latest News
3.png)